• Investing
  • Stock
  • Economy
  • Editor’s Pick
Portfolio Performance Today
Investing

Will BioNtech sustain the $140 support level?

by May 13, 2022
by May 13, 2022

BioNtech SE (NASDAQ: BNTX) is bullish this week, having gained 16.03% to trade at $158. The gains come after the company reported growth in vaccine sales. The company still expects vaccine sales to decline. This week’s rally comes after the company announced the completion of Phase II coronavirus vaccine trials in China.

BioNtech is a fundamentally strong stock. The company has more than $10 billion in cash, based on the Q1 report. BioNtech has been among the fast-growing stocks. The company is A-rated on value and growth. The F-rating on momentum means the stock is unlikely to maintain the current price trend.

A recent partnership in China where new coronavirus outbreaks are being recorded creates unique opportunities for BioNtech. Though vaccine sales to the rest of the world may decline, BioNtech will be supported by the Chinese partnership. The company remains fundamentally strong, and the strength will continue supporting the stock.

BioNtech consolidates between $140 and $180

Source – TradingView

Technical analysis shows that BioNtech continues to consolidate prices between $140 support and $180 resistance. The prices are projected to remain within this range for the better part of this year. The RSI has pointed to a potential upward trend. Nonetheless, this analysis considers that the RSI will remain between 40 and 50 for the foreseeable future.

Summary

BioNtech remains fundamentally strong on value and growth investing styles. Recent success in coronavirus vaccine Phase II trials in China will prop the decline in sales to other markets. The stock will remain between $130 and $180 as the recession bites.

The post Will BioNtech sustain the $140 support level? appeared first on Invezz.

0 comment
0
FacebookTwitterPinterestEmail

previous post
Duke Realty increases by 10% after proposed acquisition announcement
next post
What next as Moderna finds support at $130?

Related Posts

U.K. CMA eases stance on pending Microsoft-Activision merger

March 25, 2023

Tether’s Paolo Ardoino says BTC could retest its...

March 25, 2023

Flare price surging as Deutsche Bank failure push...

March 25, 2023

Netflix stock price forecast: BofA sees a 30%...

March 24, 2023

Will TikTok be banned?

March 24, 2023

Huggins sees ‘uphill battle’ for Wetherspoons stock despite...

March 24, 2023

Block share price continues to tumble after Hindenburg...

March 24, 2023

Kaiko: Liquidity situation in crypto “worsening” amid USD...

March 24, 2023

S&P 500 has been falling, but for Euro...

March 24, 2023

SMI index nears correction as UBS stock enters...

March 24, 2023

Recent Posts

  • U.K. CMA eases stance on pending Microsoft-Activision merger

    March 25, 2023
  • Tether’s Paolo Ardoino says BTC could retest its all-time high amid the banking crisis

    March 25, 2023
  • Flare price surging as Deutsche Bank failure push markets down: here’s why

    March 25, 2023
  • Netflix stock price forecast: BofA sees a 30% upside

    March 24, 2023
  • Will TikTok be banned?

    March 24, 2023
  • Huggins sees ‘uphill battle’ for Wetherspoons stock despite H1 profit

    March 24, 2023

Editors’ Picks

  • 1

    Nvidia Corporation earnings beat not sufficient to boost stock – Is it a good buy?

    February 18, 2022
  • 2

    2 Canadian marijuana stocks to keep a close eye on

    February 5, 2022
  • 3

    The IMF Should Be Eliminated, Not Expanded

    October 12, 2021
  • 4

    Headed for Insolvency: Biden Administration Increases US Obligations Worldwide

    May 29, 2022
  • 5

    Micron Technology shares are trading lower after-hours: here’s why

    September 29, 2021
  • 6

    Here’s what inflation might look like in 2022

    November 23, 2021
  • 7

    Is Clorox stock a good buy ahead of its fiscal Q1 2022 results?

    October 30, 2021
Enter Your Information Below To Receive Free Trading Ideas, Latest News, And Articles.


Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

Categories

  • Economy (1,727)
  • Editor's Pick (614)
  • Investing (5,022)
  • Stock (10)
About Us Terms & Conditions Privacy Policy Email WhiteListing Contact Us

Disclaimer: Portfolioperformancetoday.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2023 Portfolioperformancetoday.com All Rights Reserved.

Portfolio Performance Today
  • Investing
  • Stock
  • Economy
  • Editor’s Pick
Portfolio Performance Today
  • Investing
  • Stock
  • Economy
  • Editor’s Pick

Read alsox

Henry McVey on inflation: ‘there are things...

June 16, 2022

Southwest Airlines CEO warns omicron could result...

January 28, 2022

Pfizer lowers earnings guidance despite a solid...

May 3, 2022